A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

NCT06908928 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: bulumtatug fuvedotin
DRUG: bulumtatug fuvedotin

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.